NWBO reported the informational trial results in 2015. Please note that only ONE of the patients (of 46) was reported as a pseudo-progressor. Here's the quote from the NWBO press release: "20 Rapid-Progressor Patients: Patients with a new lesion = 1 cm. in size, or tumor growth of =25% both at a Baseline Visit and at Month 2 thereafter; 25 Indeterminate Patients: Patients with evidence of progression at the Baseline Visit (rendering them ineligible for the trial), followed by stable disease, modest progression and/or modest regression (or unclear tumor measurements), neither of which is enough to classify them as either a Rapid-Progressor or a Pseudo-Progressor; 1 Pseudo-Progressor: A patient whose Month 2 image showed resolution of most of the prior appearance of tumor growth that had been seen at the Baseline Visit."
The P3 trial chose PFS as the PRIMARY ENDPOINT after they had all the evidence they could measure it.
Market Data 
Markets 
AI
